These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 29418016)

  • 1. Bone mineral density in young adults with Prader-Willi syndrome: A randomized, placebo-controlled, crossover GH trial.
    Donze SH; Kuppens RJ; Bakker NE; van Alfen-van der Velden JAEM; Hokken-Koelega ACS
    Clin Endocrinol (Oxf); 2018 Jun; 88(6):806-812. PubMed ID: 29418016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone mineral density during 3 years of growth hormone in previously GH-treated young adults with PWS.
    Damen L; Grootjen LN; Donze SH; de Graaff LCG; van der Velden JAEM; Hokken-Koelega ACS
    Eur J Endocrinol; 2021 May; 184(6):773-782. PubMed ID: 33769952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone mineral density in children and adolescents with Prader-Willi syndrome: a longitudinal study during puberty and 9 years of growth hormone treatment.
    Bakker NE; Kuppens RJ; Siemensma EP; Tummers-de Lind van Wijngaarden RF; Festen DA; Bindels-de Heus GC; Bocca G; Haring DA; Hoorweg-Nijman JJ; Houdijk EC; Jira PE; Lunshof L; Odink RJ; Oostdijk W; Rotteveel J; Van Alfen AA; Van Leeuwen M; Van Wieringen H; Wegdam-den Boer ME; Zwaveling-Soonawala N; Hokken-Koelega AC
    J Clin Endocrinol Metab; 2015 Apr; 100(4):1609-18. PubMed ID: 25668198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone mineral density and effects of growth hormone treatment in prepubertal children with Prader-Willi syndrome: a randomized controlled trial.
    de Lind van Wijngaarden RF; Festen DA; Otten BJ; van Mil EG; Rotteveel J; Odink RJ; van Leeuwen M; Haring DA; Bocca G; Mieke Houdijk EC; Hokken-Koelega AC
    J Clin Endocrinol Metab; 2009 Oct; 94(10):3763-71. PubMed ID: 19622627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of cessation of GH treatment on cognition during transition phase in Prader-Willi syndrome: results of a 2-year crossover GH trial.
    Kuppens RJ; Mahabier EF; Bakker NE; Siemensma EP; Donze SH; Hokken-Koelega AC
    Orphanet J Rare Dis; 2016 Nov; 11(1):153. PubMed ID: 27852283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beneficial Effects of GH in Young Adults With Prader-Willi Syndrome: A 2-Year Crossover Trial.
    Kuppens RJ; Bakker NE; Siemensma EP; Tummers-de Lind van Wijngaarden RF; Donze SH; Festen DA; van Alfen-van der Velden JA; Stijnen T; Hokken-Koelega AC
    J Clin Endocrinol Metab; 2016 Nov; 101(11):4110-4116. PubMed ID: 27552545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two years of growth hormone treatment in adults with Prader-Willi syndrome do not improve the low BMD.
    Jørgensen AP; Ueland T; Sode-Carlsen R; Schreiner T; Rabben KF; Farholt S; Høybye C; Christiansen JS; Bollerslev J
    J Clin Endocrinol Metab; 2013 Apr; 98(4):E753-60. PubMed ID: 23436915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic health profile in young adults with Prader-Willi syndrome: results of a 2-year randomized, placebo-controlled, crossover GH trial.
    Kuppens RJ; Bakker NE; Siemensma EP; Donze SH; Stijnen T; Hokken-Koelega AC
    Clin Endocrinol (Oxf); 2017 Feb; 86(2):297-304. PubMed ID: 27689944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone Mineral Density After Cessation of GH Treatment in Young Adults Born SGA: A 5-Year Longitudinal Study.
    Smeets CCJ; van der Steen M; Renes JS; Hokken-Koelega ACS
    J Clin Endocrinol Metab; 2017 Sep; 102(9):3508-3516. PubMed ID: 28911145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endocrine and metabolic aspects of adult Prader-Willi syndrome with special emphasis on the effect of growth hormone treatment.
    Höybye C
    Growth Horm IGF Res; 2004 Feb; 14(1):1-15. PubMed ID: 14700552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth hormone treatment and bone mineral density in pediatric patients with Prader-Willi syndrome.
    Oto Y; Murakami N; Inoue T; Matsubara K; Saima S; Ogata H; Ihara H; Nagai T; Matsubara T
    J Pediatr Endocrinol Metab; 2021 Sep; 34(9):1181-1184. PubMed ID: 34162033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of 8 years of growth hormone treatment on scoliosis in children with Prader-Willi syndrome.
    Grootjen LN; Rutges JPHJ; Damen L; Donze SH; Juriaans AF; Kerkhof GF; Hokken-Koelega ACS
    Eur J Endocrinol; 2021 May; 185(1):47-55. PubMed ID: 33886496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adults with Prader-Willi syndrome have weaker bones: effect of treatment with GH and sex steroids.
    Longhi S; Grugni G; Gatti D; Spinozzi E; Sartorio A; Adami S; Fanolla A; Radetti G
    Calcif Tissue Int; 2015 Feb; 96(2):160-6. PubMed ID: 25577526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of growth hormone (GH) deficiency in previously GH-treated young adults with Prader-Willi syndrome.
    Donze SH; Damen L; van Alfen-van der Velden JAEM; Bocca G; Finken MJJ; Hoorweg-Nijman GJG; Jira PE; van Leeuwen M; Hokken-Koelega ACS
    Clin Endocrinol (Oxf); 2019 Jul; 91(1):118-123. PubMed ID: 30973645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benefits of long-term GH therapy in Prader-Willi syndrome: a 4-year study.
    Carrel AL; Myers SE; Whitman BY; Allen DB
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1581-5. PubMed ID: 11932286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of long-term continuous growth hormone treatment in children with Prader-Willi syndrome.
    de Lind van Wijngaarden RF; Siemensma EP; Festen DA; Otten BJ; van Mil EG; Rotteveel J; Odink RJ; Bindels-de Heus GC; van Leeuwen M; Haring DA; Bocca G; Houdijk EC; Hoorweg-Nijman JJ; Vreuls RC; Jira PE; van Trotsenburg AS; Bakker B; Schroor EJ; Pilon JW; Wit JM; Drop SL; Hokken-Koelega AC
    J Clin Endocrinol Metab; 2009 Nov; 94(11):4205-15. PubMed ID: 19837938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response to growth hormone treatment in Prader-Willi syndrome: auxological criteria versus genetic diagnosis.
    Scheermeyer E; Hughes I; Harris M; Ambler G; Crock P; Verge CF; Craig ME; Bergman P; Werther G; van Driel M; Davies PS; Choong CS
    J Paediatr Child Health; 2013 Dec; 49(12):1045-51. PubMed ID: 23781979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized controlled GH trial: effects on anthropometry, body composition and body proportions in a large group of children with Prader-Willi syndrome.
    Festen DA; de Lind van Wijngaarden R; van Eekelen M; Otten BJ; Wit JM; Duivenvoorden HJ; Hokken-Koelega AC
    Clin Endocrinol (Oxf); 2008 Sep; 69(3):443-51. PubMed ID: 18363884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two years of growth hormone therapy in young children with Prader-Willi syndrome: physical and neurodevelopmental benefits.
    Myers SE; Whitman BY; Carrel AL; Moerchen V; Bekx MT; Allen DB
    Am J Med Genet A; 2007 Mar; 143A(5):443-8. PubMed ID: 17103437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained benefits of growth hormone on body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome are dose-dependent.
    Carrel AL; Myers SE; Whitman BY; Allen DB
    J Pediatr Endocrinol Metab; 2001; 14(8):1097-105. PubMed ID: 11592566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.